Loading organizations...
§ Private Profile · Copenhagen, Denmark
Biotech firm developing probiotic supplements for PFAS reduction in humans, supporting natural removal via the gut.
CAMBIOTICS is a biotechnology company developing probiotic solutions designed to reduce per- and polyfluoroalkyl substances (PFAS) in the human body by facilitating natural excretion through the digestive tract. The company's flagship product, 46&, utilizes two specific non-GMO probiotic strains to bioaccumulate these synthetic forever chemicals and is scheduled for commercial launch in 2026 following the completion of clinical trials. To support its clinical research and upcoming product rollout, the enterprise has raised €4 million in seed funding to date. This financing round was led by Collaborative Fund, and the firm has also established strategic partnerships with Quest Diagnostics and LIFESCAN Wellness Centers to support comprehensive PFAS blood testing and health management. Spun out from toxicology research conducted at the University of Cambridge, the company was founded by Dr. Anna Lindell and Peter Holme Jensen.
CAMBIOTICS has raised $52.7M across 2 funding rounds.
CAMBIOTICS has raised $52.7M in total across 2 funding rounds.
CAMBIOTICS has raised $52.7M across 2 funding rounds. Most recently, it raised $48.0M Seed in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 12, 2026 | $48M Seed | Collaborative Fund | — | Announced |
| Feb 2, 2026 | $4.7M Seed | Collaborative Fund | Export And Investment Fund, True. | Announced |
CAMBIOTICS has raised $52.7M in total across 2 funding rounds.
CAMBIOTICS's investors include Collaborative Fund, Export and Investment Fund, True..